C-mo Medical Solutions, a provider of a wearable fully-automated real-time cough assessment and recording technology, announced an extension to its seed investment round.
Novalis Biotech led the investment round with participation from Novalis Biotech, Boehringer Ingelheim Venture Fund, Portugal Ventures, and High-Tech Gründerfonds (HTGF).
The extension round now brings the company’s total seed funding to date to €4.8 million, according to the press release.
According to Diogo Tecelão, co-founder and CEO of C-mo Medical Solutions, this extension of the seed investment round will allow the company to further explore and unlock the full potential of cough assessment, namely by expanding the capabilities and applications of their technology.
Commenting on the funding news, Diogo Tecelão said: C-mo Medical Solutions is committed to solving the pressing need to better assess chronic cough, a symptom that affects more than 700 million adults worldwide. “Cough is a clinically rich symptom that holds valuable information about the patient’s health. However, the lack of tools to assess and manage chronic cough remains a major unmet medical need. Our mission is to change that!”
“Our unique technology analyses the subtle characteristics of the patient’s cough, translating them into actionable insights that add significant value in key several use-cases. C-mo has the potential to greatly speed up diagnosis, optimize treatment courses, improve disease management, and support pharmaceutical research,” added Diogo Tecelão.
Novalis Biotech, an early-stage venture capital firm in technologies that revolutionize healthcare, has invested millions of dollars in bioinformatics, genomics, personalized medicine, clinical research or manufacturing tools, and diagnostics. More recently, it has invested €1.9 million in Grapheal, a developer of wearable biosensors for on-site diagnostics and remote patient monitoring for wound care.
Wearable health monitoring solutions providers have raised nearly $10 billion in venture capital funding to date, according to our funding database.
More recently, SiBionics, a provider of a wearable device system to track blood sugar in real-time, raised $72 million in Series D funding led by Shanghai Biomedical Industrial Equity Investment Fund and Guangdong Chinese Medicine and Mass Health Fund with participation from Industrial Securities Capital, Next Capital, China New Town, Source Code Capital, Riverhead Capital, Qianhai FOF, and Fortune Capital.
In another deal, Cardiosense, a provider of an AI-powered wearable system for the early detection of cardiovascular disease, raised $15.1 million in Series A funding. Broadview Ventures and Hatteras Venture Partners led the investment round with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations.
Click here to read more about the latest digital health funding news…